- Home
- DRUG vs FLYX Comparison
DRUG vs FLYX Comparison
Compare DRUG & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- FLYX
- Stock Information
- Founded
- DRUG 2019
- FLYX 2015
- Country
- DRUG United States
- FLYX United States
- Employees
- DRUG N/A
- FLYX N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- FLYX Blank Checks
- Sector
- DRUG Health Care
- FLYX Finance
- Exchange
- DRUG Nasdaq
- FLYX Nasdaq
- Market Cap
- DRUG 210.7M
- FLYX 190.6M
- IPO Year
- DRUG N/A
- FLYX N/A
- Fundamental
- Price
- DRUG $32.38
- FLYX $2.10
- Analyst Decision
- DRUG
- FLYX Hold
- Analyst Count
- DRUG 0
- FLYX 1
- Target Price
- DRUG N/A
- FLYX N/A
- AVG Volume (30 Days)
- DRUG 382.4K
- FLYX 24.1K
- Earning Date
- DRUG 11-26-2024
- FLYX 01-01-0001
- Dividend Yield
- DRUG N/A
- FLYX N/A
- EPS Growth
- DRUG N/A
- FLYX N/A
- EPS
- DRUG N/A
- FLYX N/A
- Revenue
- DRUG N/A
- FLYX $311,873,000.00
- Revenue This Year
- DRUG N/A
- FLYX $15.91
- Revenue Next Year
- DRUG N/A
- FLYX $39.64
- P/E Ratio
- DRUG N/A
- FLYX N/A
- Revenue Growth
- DRUG N/A
- FLYX N/A
- 52 Week Low
- DRUG $0.93
- FLYX $1.79
- 52 Week High
- DRUG $79.02
- FLYX $24.21
- Technical
- Relative Strength Index (RSI)
- DRUG 43.69
- FLYX 33.41
- Support Level
- DRUG $36.02
- FLYX $2.05
- Resistance Level
- DRUG $44.70
- FLYX $2.29
- Average True Range (ATR)
- DRUG 5.79
- FLYX 0.18
- MACD
- DRUG -3.22
- FLYX 0.03
- Stochastic Oscillator
- DRUG 6.26
- FLYX 47.37
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 90 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.